Trial Profile

A Phase III, Multicenter, Double Blind, Randomized Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL In Healthy Infants

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Yellow fever vaccine-Serum Institute of India (Primary) ; Measles mumps and rubella virus vaccine; Meningococcal vaccine group A conjugate
Indications Yellow fever
Focus Pharmacodynamics; Registrational
Sponsors Serum Institute of India

Most Recent Events

22 Nov 2023 Planned End Date changed from 30 Aug 2024 to 30 Jan 2024.
22 Nov 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Jan 2024.
22 Nov 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com